Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.
Pietro LamperticoStefan MaussMarcello PersicoStephen T BarclaySteven MarxKristina LohmannMark BondinZhenZhen ZhangFiona MarraPamela S BelperioHeiner WedemeyerSteven FlammPublished in: Advances in therapy (2020)
Expanding the number of patients eligible for the shortened treatment duration will potentially increase treatment initiation and completion, particularly in underserved populations, contributing to the elimination of hepatitis C virus.